We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Novel Diagnostic Device Profiles Population of Gut Microbiome

By LabMedica International staff writers
Posted on 05 Aug 2019
Researchers used a three-dimensional (3D) printer to manufacture a novel pill-like diagnostic tool capable of profiling the bacterial species comprising the gut microbiome in the critical area between the stomach and the colon.

Investigators at Tufts University (Medford/Somerville, MA, USA) recently described a novel non-invasive diagnostic tool capable of providing a profile of microbiome populations throughout the entire GI tract. More...
The device was manufactured in a three-dimensional printer.

The surface of the pill was covered with a pH-sensitive coating, so that it did not absorb any substances until it passed through the stomach and entered the small intestine, where the coating dissolved. A semi-permeable membrane separated two chambers in the pill - one containing helical channels that captured bacteria and the other containing a calcium salt-filled chamber, which created an osmotic flow across the membrane that forced the bacteria into the helical channels. A small magnet in the pill enabled controlled movement and targeting via a magnet outside the body. Finally, a fluorescent dye in the salt chamber marked the pill for easy identification after it left the body.

The pill's sampling performance was characterized using realistic in vitro models and validated in vivo in pigs and primates. So far, results have indicated that the bacterial populations recovered from the pills’ microfluidic channels closely resembled the bacterial population demographics of the microenvironment to which the pill was exposed. Despite these promising results, clinical trials will be needed to determine if the pill can be adapted for routine use in humans.

"We are learning quite a lot about the role of gut microbiome in health and disease. However, we know very little about its biogeography," said senior author Dr. Sameer Sonkusale, professor of electrical and computer engineering at Tufts University. "The pill will improve our understanding of the role of spatial distribution in the microbiome profile to advance novel treatments and therapies for a number of diseases and conditions."

The microbiome profiler was described in the July 19, 2019, online edition of the journal Advanced Intelligent Systems.

Related Links:
Tufts University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.